ROCKVILLE, Md. , Feb. 22, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Monday, March 1, 2021 , at 4:30 p.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2020 , and recent operational highlights.
To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international) and enter the passcode 6298809. To access a live or recorded webcast of the call, please visit the Investors section of the REGENXBIO website at www.regenxbio.com . The recorded webcast will be available for approximately 30 days following the call.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
Contacts:
Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com
Investors:
Brendan Burns , 212-600-1902
brendan@argotpartners.com
Media:
David Rosen , 212-600-1902
david.rosen@argotpartners.com
View original content to download multimedia: http://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-march-1-to-discuss-fourth-quarter-and-full-year-2020-financial-results-and-recent-operational-highlights-301232648.html
SOURCE REGENXBIO Inc.
![](https://rt.prnewswire.com/rt.gif?NewsItemId=PH86540&Transmission_Id=202102221605PR_NEWS_USPR_____PH86540&DateId=20210222)